MDM2 and p53 Gene Variants and Their Impact on Lymphoma
Author Information
Author(s): Bittenbring Joerg, Parisot Frédérique, Wabo Alain, Mueller Monika, Kerschenmeyer Lynn, Kreuz Markus, Truemper Lorenz, Landt Olfert, Menzel Alain, Pfreundschuh Michael, Roemer Klaus
Primary Institution: University of Saarland Medical School
Hypothesis
Are SNP309 and SNP72 associated with diffuse large B-cell lymphoma in women and correlated with age of onset, diagnosis, or patient's survival?
Conclusion
Neither SNP309 nor SNP72 seem to be correlated with age of onset, diagnosis, or survival of patients with diffuse large B-cell lymphoma.
Supporting Evidence
- The study included 311 patients diagnosed with aggressive non-Hodgkin lymphoma.
- 512 healthy controls were used for comparison.
- No significant differences in genotype frequencies were observed between patients and controls.
- The age of onset was similar in men and women.
- Neither SNP309 nor SNP72 had a significant influence on event-free and overall survival.
Takeaway
The study looked at two gene changes to see if they affect lymphoma risk or survival, but found they don't seem to matter for patients in central Europe.
Methodology
SNP309 and SNP72 were PCR-genotyped in a case-control study that included 512 controls and 311 patients diagnosed with aggressive NHL.
Limitations
The study may not be generalizable to populations outside of central European Caucasians.
Participant Demographics
The study included 311 patients diagnosed with aggressive non-Hodgkin lymphoma and 512 healthy controls, primarily central European Caucasians.
Statistical Information
P-Value
p = 0.33
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website